spironolactone has been researched along with fosinopril in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B | 1 |
| Belenkov, IuN; Belianko, IE; Dolotov, VK; Gerasimova, VV; Khovrin, VV; Konstantinov, BA; Koroteev, AV; Kulagina, TIu; Mareev, VIu; Rebunenkov, GV; Sandrikov, VA; Skvortsov, AA; Sychev, AV; Tereshchenko, SN | 1 |
| Kazory, A; Weiner, ID | 1 |
| Buyukhatipoglu, H; Tiryaki, O; Usalan, C | 1 |
| Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A | 1 |
1 review(s) available for spironolactone and fosinopril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for spironolactone and fosinopril
| Article | Year |
|---|---|
Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Chronic Disease; Diet, Sodium-Restricted; Down-Regulation; Drug Therapy, Combination; Female; Fibrinolysis; Fosinopril; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Renin; Spironolactone; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2010 |
6 other study(ies) available for spironolactone and fosinopril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Chronic Disease; Disease Models, Animal; Electrocardiography, Ambulatory; Fosinopril; Heart Rate; Heart Ventricles; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Random Allocation; Rats; Rats, Wistar; Spironolactone; Time Factors; Ventricular Dysfunction; Ventricular Premature Complexes | 2001 |
[Implantation of an extracardiac mesh in the treatment of dilated cardiomyopathy: the TOLK Study (Therapevticheskoe Operativnoe Lechenie Kardiomyopatye)].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Diuretics; Female; Fosinopril; Humans; Intra-Aortic Balloon Pumping; Male; Middle Aged; Postoperative Care; Propanolamines; Quality of Life; Radiography, Thoracic; Spironolactone; Surgical Mesh; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vasodilator Agents; Ventricular Remodeling | 2005 |
Primary hyperaldosteronism in a patient with end-stage renal disease.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Follow-Up Studies; Fosinopril; Humans; Hyperaldosteronism; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renal Dialysis; Renin; Spironolactone | 2007 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Exercise Tolerance; Fosinopril; Glucosides; Heart Failure; Male; Myocardial Infarction; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |